<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of stress echocardiography</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of stress echocardiography</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of stress echocardiography</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adelaide M Arruda-Olson, MD, PhD, FASE, FAHA, FAMIA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Warren J Manning, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Echocardiography enables evaluation of cardiac function at rest, during pharmacologic stress, and during or immediately following dynamic exercise. Exercise two-dimensional (2D) transthoracic imaging is used primarily to detect the presence and extent of coronary artery disease by provoking regional ischemia with resulting wall motion abnormalities. The addition of exercise Doppler permits evaluation of exercise-induced changes in valvular function (eg, severity of mitral regurgitation/mitral stenosis gradient), pulmonary artery systolic pressure, left ventricular outflow tract gradient, and global left ventricular systolic and diastolic function.</p><p>Stress echocardiography can be accomplished using either exercise (treadmill or bicycle) or pharmacologic agents (predominantly <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>) as the stress mechanism [<a href="#rid1">1-3</a>]. Microbubble ultrasound-enhancing agents may be useful in enhancing endocardial border definition when two or more segments of the left ventricle are not well visualized. (See  <a class="medical medical_review" href="/z/d/html/5313.html" rel="external">"Contrast echocardiography: Clinical applications"</a> and  <a class="medical medical_review" href="/z/d/html/5301.html" rel="external">"Contrast echocardiography: Contrast agents, safety, and imaging technique"</a>.)</p><p>An overview of the indications, contraindications, techniques, and safety of stress echocardiography will be provided here. Exercise treadmill testing and radionuclide myocardial perfusion imaging, as well as the advantages and disadvantages of stress echocardiography as compared with other stress modalities, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results"</a> and  <a class="medical medical_review" href="/z/d/html/5328.html" rel="external">"Overview of stress radionuclide myocardial perfusion imaging"</a> and  <a class="medical medical_review" href="/z/d/html/1502.html" rel="external">"Selecting the optimal cardiac stress test"</a>.)</p><p class="headingAnchor" id="H406169795"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>There are several specific indications for stress echocardiography [<a href="#rid3">3-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of patients with known or suspected coronary artery disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of myocardial viability. (See  <a class="medical medical_review" href="/z/d/html/1528.html" rel="external">"Dobutamine stress echocardiography in the evaluation of hibernating myocardium"</a> and  <a class="medical medical_review" href="/z/d/html/1474.html" rel="external">"Evaluation of hibernating myocardium"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of dyspnea of possible cardiac origin. (See  <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for pulmonary artery hypertension, as pulmonary artery systolic pressure can be estimated at rest and post-exercise. (See  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of mitral valve disease, including mitral stenosis gradient and mitral regurgitation. (See  <a class="medical medical_review" href="/z/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis", section on 'Exercise testing'</a> and  <a class="medical medical_review" href="/z/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation", section on 'Stress testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of aortic stenosis. Stress echocardiography may be reasonable and helpful in patients with low gradient aortic stenosis. (See  <a class="medical medical_review" href="/z/d/html/8114.html" rel="external">"Clinical manifestations and diagnosis of low gradient severe aortic stenosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of left ventricular outflow tract gradients, mitral regurgitation, and pulmonary hypertension in patients with hypertrophic cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Exercise testing'</a>.)</p><p></p><p>The baseline (resting) echocardiographic imaging performed prior to stress testing is described below. (See <a class="local">'Baseline echocardiography'</a> below.)</p><p class="headingAnchor" id="H197711631"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Contraindications to exercise and pharmacologic stress echocardiography are the same as those for standard exercise electrocardiographic (ECG) testing. Contraindications for all stress testing modalities include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Acute coronary syndromes</p><p class="bulletIndent1"><span class="glyph">●</span>Severe cardiac arrhythmias</p><p class="bulletIndent1"><span class="glyph">●</span>Malignant hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Significant left ventricular outflow tract obstruction</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic severe aortic stenosis [<a href="#rid2">2</a>]</p><p></p><p>Contraindications to <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography include tachyarrhythmias and systemic hypertension [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results", section on 'Contraindications'</a>.)</p><p>Some have considered abdominal aortic aneurysm to be a relative contraindication to exercise testing or <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography [<a href="#rid6">6,7</a>]. However, there is evidence that such stress testing can be safely performed in these patients. In a review of 262 patients with an abdominal aortic aneurysm diameter &gt;4 cm (average 5.5 cm), one patient (0.4 percent) with a 6.1 cm aneurysm had a contained rupture 12 hours after exercise, which was successfully repaired [<a href="#rid6">6</a>]. In 98 patients with abdominal aortic aneurysms ≥4 cm who underwent dobutamine stress echocardiograms, there were no vascular complications [<a href="#rid7">7</a>]. </p><p class="headingAnchor" id="H406169622"><span class="h1">STRESS TECHNIQUES</span></p><p class="headingAnchor" id="H2"><span class="h2">Exercise two-dimensional echocardiography</span><span class="headingEndMark"> — </span>Exercise stress is preferable to pharmacologic stress for patients who are capable of performing an exercise test, as exercise capacity and the hemodynamic response to exercise are important predictors of outcomes [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/1502.html" rel="external">"Selecting the optimal cardiac stress test"</a> and  <a class="medical medical_review" href="/z/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results"</a>.)</p><p class="headingAnchor" id="H3"><span class="h3">Protocols</span><span class="headingEndMark"> — </span>The practice guidelines from the American Society of Echocardiography (ASE) recommend symptom-limited exercise according to standard protocols using either a treadmill or bicycle [<a href="#rid2">2,3</a>]. These guidelines note that if evaluation of wall motion is the main purpose of the test, then treadmill exercise is usually used, whereas if stress Doppler information is desired, supine bicycle exercise should be considered because it enables Doppler as well as wall motion evaluation during each stage of exercise [<a href="#rid2">2,3</a>]. As with any exercise stress test, exercise should be performed until the patient feels that he/she cannot exercise further due to fatigue or symptoms, although in some instances there may be appropriate endpoints determined by the provider or the protocol. (See  <a class="medical medical_review" href="/z/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results", section on 'Test endpoints'</a>.)</p><p class="headingAnchor" id="H4"><span class="h4">Treadmill</span><span class="headingEndMark"> — </span>Exercise echocardiography is most commonly performed using a treadmill protocol  (<a class="graphic graphic_table graphicRef70044" href="/z/d/graphic/70044.html" rel="external">table 1</a>). Echocardiographic images are acquired prior to and immediately after completion of exercise [<a href="#rid2">2,3,8,9</a>]. This method requires that the patient transfer from the treadmill into a recumbent position for imaging within a few seconds so that a complete set of images can be obtained as rapidly as possible, usually within 60 seconds after cessation of exercise. Use of digitized images permits review of multiple cardiac cycles, as well as side-by-side comparison of these images. This approach maximizes accuracy of interpretation. Continuous recording of images is also recommended as backup [<a href="#rid2">2,3</a>]. </p><p>For maximal diagnostic accuracy, images should be obtained prior to the heart rate decreasing toward baseline. Early image acquisition is necessary since ischemia-induced wall motion abnormalities may resolve rapidly as the heart rate slows, causing a decrease in the sensitivity of the test, especially for single vessel disease. The experience and competence of a laboratory's clinician/sonographer team influence the reliability of this test [<a href="#rid2">2,3</a>]. </p><p class="headingAnchor" id="H5"><span class="h4">Supine or upright bicycle ergometry</span><span class="headingEndMark"> — </span>Some laboratories perform stress echocardiography using supine or upright bicycle ergometry. A typical symptom-limited supine bicycle protocol starts at a workload of 25 or 30 watts and increases by 25 or 30 watt increments every three minutes until an endpoint is achieved.</p><p>A major advantage of supine bicycle ergometry is that it allows for continuous monitoring of wall motion during exercise. Imaging throughout the study may permit detection of the onset of wall motion abnormalities and improve sensitivity of detection of coronary artery disease [<a href="#rid10">10,11</a>]. Moreover, acquisition of Doppler imaging during each stage of exercise is also feasible during supine bicycle exercise. </p><p class="headingAnchor" id="H6"><span class="h2">Pharmacologic stress echocardiography</span><span class="headingEndMark"> — </span>Pharmacologic stress is employed in patients who are unable to perform exercise testing. In addition, it may be preferable to exercise testing for preoperative risk and myocardial viability assessment since the majority of data validating stress echocardiography for myocardial viability involved pharmacologic (largely <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>) stress. </p><p>Pharmacologic stress testing most commonly involves the administration of <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> with the addition of <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> as needed to achieve the target heart rate [<a href="#rid2">2,3,12-15</a>]. The American Society of Echocardiography (ASE) guidelines recommend dobutamine as preferable to vasodilators (eg, <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a>, <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>, <a class="drug drug_general" data-topicid="9462" href="/z/d/drug information/9462.html" rel="external">regadenoson</a>) as there is greater experience using dobutamine for stress echocardiography in the United States [<a href="#rid3">3</a>]. However, dobutamine and vasodilators are equally potent ischemic stressors for inducing wall abnormalities in the presence of a critical epicardial coronary artery stenosis [<a href="#rid1">1,3</a>]. As such, dipyridamole is a popular pharmacologic regimen for stress echocardiography in Europe [<a href="#rid16">16-18</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Dobutamine stress echocardiography</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> dosage and protocols for the indications of assessment of obstructive coronary artery disease and viability are provided. </p><p class="headingAnchor" id="H2469549166"><span class="h4">Assessment of obstructive coronary artery disease</span><span class="headingEndMark"> — </span>The standard <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress test components are [<a href="#rid2">2,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Graded <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> infusion in five three-minute stages starting at 5 mcg/kg/minute, followed by 10, 20, 30, and 40 mcg/kg/minute  (<a class="graphic graphic_figure graphicRef80855" href="/z/d/graphic/80855.html" rel="external">figure 1</a>). Some experts start the graded infusion at a lower dosage (eg, 2.5 mcg/kg/minute) while others use an accelerated protocol of 15, 30, and 45 mcg/kg/minute. Some experts omit the first low-dose stage when no viability evaluation is sought.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">Atropine</a>, in divided doses of 0.5 mg each to a total of 2 mg, should be administered as needed to achieve target heart rate. Atropine increases the sensitivity of <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography in patients receiving beta-blockers and in those with single-vessel disease [<a href="#rid19">19-21</a>]. Some laboratories also use a sustained isometric hand grip or a low-level dynamic foot exercise (with or without atropine) in the late stages of the dobutamine protocol as a supplemental maneuver to achieve peak heart rate. (See <a class="local">'Handgrip exercise'</a> below.)</p><p></p><p>During <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography, echocardiographic images are acquired prior to the start of the dobutamine infusion, at the completion of each stage, and during recovery. </p><p>Variations from the standard <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> protocol have been proposed. Some laboratories use a sixth dose of 50 mcg/kg/minute; others, based on pharmacokinetic data, extend the 40 mcg infusion to five minutes. Some omit the first low-dose (5 mcg/kg/min) stage when no viability evaluation is sought. Accelerated dobutamine protocols have been described [<a href="#rid22">22,23</a>]. </p><p>The standard endpoint for <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography is the achievement of target heart rate, defined as at least 85 percent of the age-predicted maximum heart rate. However, the test may also be terminated following the development of significant symptoms, new or worsening wall motion abnormalities of moderate degree, significant arrhythmias, hypotension (systolic blood pressure less than 90 mmHg), or severe hypertension [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results", section on 'Test endpoints'</a>.)</p><p class="headingAnchor" id="H3941002700"><span class="h4">Viability assessment</span><span class="headingEndMark"> — </span>A <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiogram can assess myocardial viability and contractile reserve. (See  <a class="medical medical_review" href="/z/d/html/1528.html" rel="external">"Dobutamine stress echocardiography in the evaluation of hibernating myocardium"</a> and  <a class="medical medical_review" href="/z/d/html/1474.html" rel="external">"Evaluation of hibernating myocardium"</a>.)</p><p><a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">Dobutamine</a> dosing for viability assessment starts at a lower initial dose than for assessment of coronary artery disease. We use the following dosing:</p><p class="bulletIndent1"><span class="glyph">●</span>Continuous <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> infusion initiated<strong> </strong>at<strong> </strong>2.5 mcg/kg/minute, and increasing at five-minute intervals in 2.5 mcg/kg/minute increments until a contractile response is noted, up to a maximum dose of 10 mcg/kg/minute [<a href="#rid2">2,24,25</a>].</p><p></p><p class="headingAnchor" id="H6715897"><span class="h4">Effect of beta blocker therapy</span><span class="headingEndMark"> — </span>Use of beta-blockers may attenuate heart rate response as well as evidence of myocardial ischemia during <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography [<a href="#rid18">18,26</a>]. However, the effect of beta-blockers on heart rate response to dobutamine can usually be overcome by the administration of <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> [<a href="#rid21">21</a>]. Moreover, performing the stress echocardiogram while the patient stays on all medications, including beta-blockers, may be useful for assessment of treatment efficacy. Some stress echocardiography laboratories recommend withholding beta-blockers prior to the test while others typically recommend continuation of beta-blockers and all cardiac medications prior to stress echocardiograms [<a href="#rid27">27</a>]. While the safety and prognostic value of dobutamine stress echocardiography for patients who continue taking their home medication is well established, the referring care provider may decide to withhold beta-blockers in certain circumstances (eg, to maximize the sensitivity of the test for the initial diagnosis of coronary heart disease) [<a href="#rid28">28-31</a>]. </p><p class="headingAnchor" id="H11"><span class="h3">Vasodilator stress echocardiography</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">Dipyridamole</a> is administered at up to 0.84 mg/kg in two separate infusions: 0.56 mg/kg over four minutes ("standard dose"), followed by four minutes of no dose and, if an adequate physiologic response is not achieved, then an additional 0.28 mg/kg is given over two minutes. If no endpoint is reached following the second infusion (total of 0.84 mg/kg), then <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> (doses of 0.25 mg, up to a maximum of 1 mg) may be administered [<a href="#rid1">1</a>].</p><p><a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">Adenosine</a> is typically infused at a maximum dose of 140 mcg/kg/minute over six minutes [<a href="#rid1">1</a>]. Imaging is performed prior to and after starting adenosine infusion. Adenosine is a shorter-acting agent employed for myocardial perfusion contrast echocardiography and, to a lesser extent, to detect stress-induced changes in wall motion, but this method has not been in wide clinical use. Vasodilator stress may be better suited for perfusion than wall motion analysis [<a href="#rid26">26</a>]. </p><p>Both <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> and <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> are contraindicated in patients with reactive airway obstruction or significant hypotension [<a href="#rid2">2</a>]. </p><p class="headingAnchor" id="H12"><span class="h2">Pacing</span><span class="headingEndMark"> — </span>In selected patients with a permanent pacemaker, increasing the pacing rate to facilitate achievement of target heart rate may be used; this stress method is combined with <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> infusion [<a href="#rid2">2</a>] , starting with dobutamine infusion following the usual protocol and then holding the infusion at 20 mcg. At this dose of dobutamine, we start a stepwise increase of the heart rate by increase pacing rate until achievement of the target heart rate. During recovery the pacing rate is progressively reduced at one-minute intervals. </p><p class="headingAnchor" id="H13"><span class="h2">Handgrip exercise</span><span class="headingEndMark"> — </span>Handgrip may be used as an adjunct to exercise or <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography [<a href="#rid32">32,33</a>]. During the last stage of exercise or dobutamine infusion and 30 seconds before acquiring the peak exercise images, patients are asked to exert a sustained grip on a tennis ball. The hand grip response reliably raises blood pressure at least 10 mmHg and usually also increases heart rate; superimposed on the maximum achieved levels, this augmentation results in a "bonus" increment in rate pressure product. </p><p class="headingAnchor" id="H406171424"><span class="h1">IMAGING TECHNIQUES</span></p><p class="headingAnchor" id="H406171761"><span class="h2">Baseline echocardiography</span><span class="headingEndMark"> — </span>The baseline (resting) echocardiogram obtained prior to stress testing should include a screening assessment of ventricular function, chamber sizes, left ventricular wall thicknesses, aortic root diameter, pericardial effusions, and gross valvular structure and function, including an estimate of pulmonary arterial systolic pressure using the peak tricuspid regurgitation velocity. Baseline and stress images are acquired in a variety of standard echocardiographic windows, including apical (four-chamber, long axis, and two-chamber), and parasternal (long and short axis) [<a href="#rid34">34-39</a>]. Rest imaging allows screening and prompt identification of potential etiologies for cardiac symptoms [<a href="#rid3">3</a>]. It also allows the diagnosis of ancillary conditions in the setting of coronary artery disease, such as intracavitary thrombus or ischemic mitral regurgitation. (See  <a class="medical medical_review" href="/z/d/html/5319.html" rel="external">"Transthoracic echocardiography: Normal cardiac anatomy and tomographic views"</a>.)</p><p class="headingAnchor" id="H406171767"><span class="h2">Two-dimensional imaging</span><span class="headingEndMark"> — </span>When stress echocardiography is performed to evaluate coronary heart disease, the main goal of two-dimensional (2D) imaging is side-by-side comparison of images for assessment of global and regional left ventricular systolic function at rest and immediately after stress. Images are also compared with pre-peak and peak stress, during pharmacologic stress or with bicycle exercise. With stress, the normal left ventricle becomes hypercontractile, cavity size is reduced, and ejection fraction increases [<a href="#rid2">2,3</a>]. Various professional society recommendations for chamber quantification have suggested either a 16- or 17-segment model for left ventricular regional wall motion analysis  (<a class="graphic graphic_figure graphicRef55855" href="/z/d/graphic/55855.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef64968" href="/z/d/graphic/64968.html" rel="external">figure 3</a>) [<a href="#rid3">3,40,41</a>]. Function in each segment is graded (normal, hyperdynamic, hypokinetic, akinetic, dyskinetic, or aneurysmal) at rest and with stress. In addition, global left ventricular systolic function and cavity size are evaluated. (See  <a class="medical medical_review" href="/z/d/html/5319.html" rel="external">"Transthoracic echocardiography: Normal cardiac anatomy and tomographic views"</a>.)</p><p>Detection of segmental left ventricular dysfunction is useful in diagnosing and localizing obstructive coronary artery disease  (<a class="graphic graphic_figure graphicRef55855" href="/z/d/graphic/55855.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef61847" href="/z/d/graphic/61847.html" rel="external">figure 4</a>). The development of new or worsening segmental wall motion with stress suggests presence of hemodynamically significant coronary artery stenoses supplying the abnormal segments. Decrease of global left ventricular ejection fraction, and/or increased left ventricular end-systolic volume, suggest presence of severe obstructive coronary arterial disease such as flow-limiting left main stenosis or severe multivessel coronary artery disease. </p><p>Low-dose <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography enables identification of dysfunctional but viable myocardial segments. In segments that have resting dysfunction but are viable (hibernating or stunned), low-dose dobutamine infusion leads to improved contractility [<a href="#rid3">3</a>]. As the dobutamine dose is increased, a biphasic response is detected with the segmental motion improving at low-dose and then deteriorating at a higher dose to a level of dysfunction that is worse than it was at rest [<a href="#rid12">12,13,42-44</a>]. Such a response is highly specific for identifying a dysfunctional hibernating segment that is served by a stenotic coronary artery. The highest sensitivity for viability detection is obtained by identification of improvement with low-dose dobutamine; highest specificity is achieved when a biphasic response occurs. (See  <a class="medical medical_review" href="/z/d/html/1528.html" rel="external">"Dobutamine stress echocardiography in the evaluation of hibernating myocardium"</a> and  <a class="medical medical_review" href="/z/d/html/1474.html" rel="external">"Evaluation of hibernating myocardium"</a>.) </p><p class="headingAnchor" id="H406171773"><span class="h2">Doppler imaging</span><span class="headingEndMark"> — </span>Doppler echocardiography enables measurement of flow velocities and pressure gradients. Because Doppler recordings display instantaneous changes in these parameters, this is an excellent technique for the study of hemodynamic response to exercise or pharmacologic stress.</p><p>Doppler examination following stress should be individualized based on the findings from the baseline (resting) echocardiogram as well as the indications for the study. The common potential targets for Doppler examination following stress testing include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitral valve</strong> – Changes in mitral stenosis gradient or mitral regurgitation following stress</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aortic valve</strong> – Evaluation of aortic valvular gradients in suspected low-flow, low-gradient aortic stenosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tricuspid valve</strong> – Assessment of tricuspid regurgitation velocity for estimation of pulmonary artery systolic pressure in patients with suspected pulmonary hypertension</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Left ventricular outflow tract (LVOT)</strong> – Evaluation for inducible or worsening LVOT gradient in suspected or known hypertrophic cardiomyopathy</p><p></p><p class="headingAnchor" id="H406171779"><span class="h2">Use of microbubble ultrasound-enhancing agents</span><span class="headingEndMark"> — </span>Microbubble ultrasound-enhancing agents<strong> </strong>improve left ventricular endocardial border definition during stress echocardiography. Though the administration of an ultrasound-enhancing agent requires intravenous access, use of these agents increases the number of interpretable left ventricular wall segments, improves the accuracy of less experienced readers, enhances diagnostic confidence, and reduces the need for additional noninvasive tests [<a href="#rid45">45-48</a>]. </p><p class="headingAnchor" id="H11969949"><span class="h3">Indications for ultrasound-enhancing agents</span><span class="headingEndMark"> — </span>Ultrasound-enhancing agents should be used when two or more contiguous segments cannot be visualized with resting native imaging, coronary artery territory cannot be completely visualized, or Doppler signals are inadequately recorded [<a href="#rid3">3,49</a>]. </p><p>Clinical characteristics suggesting the need for ultrasound-enhancing agents during stress echocardiography include older age, male sex, smoking, presence of multiple coronary artery disease risk factors, higher body mass index, chronic lung disease, referral for <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress, history of coronary artery disease, and abnormal baseline electrocardiogram [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/5313.html" rel="external">"Contrast echocardiography: Clinical applications"</a>.)</p><p>In addition to enhancement of endocardial border definition, ultrasound-enhancing agents can be helpful for augmenting Doppler signals [<a href="#rid49">49</a>]. Technically suboptimal right heart Doppler signals can usually be improved by intravenous agitated <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>. In selected cases, technically suboptimal left heart Doppler signals could be improved by the use of intravenous injection of microbubble ultrasound contrast agents [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H197712016"><span class="h1">SAFETY</span></p><p class="headingAnchor" id="H11969993"><span class="h2">General concerns</span><span class="headingEndMark"> — </span>There are <strong>no known adverse effects</strong> from diagnostic ultrasound at clinical imaging frequencies, so the addition of echocardiographic imaging to stress testing (either exercise or pharmacologic) does not alter the underlying risk of the stress test. (See  <a class="medical medical_review" href="/z/d/html/5316.html" rel="external">"Echocardiography essentials: Physics and instrumentation", section on 'Bioeffects and safety'</a>.)</p><p>As with any stress test, the patient's electrocardiogram, heart rate, and blood pressure should be monitored throughout the test and during recovery, and the patient should be frequently queried about the development of symptoms. The monitoring of the patient during stress testing and the interpretation of the results are discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results"</a>.)</p><p>The risks of exercise or <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography testing are low. In one cohort of more than 60,000 stress echocardiograms (including more than 25,000 exercise and more than 35,000 dobutamine), life-threatening complications were very rare (0.015 percent of exercise stress echocardiograms and 0.18 percent of dobutamine stress echocardiograms) [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H197712022"><span class="h2">Safety of dobutamine administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">Dobutamine</a> is generally safe and well tolerated when used in stress testing [<a href="#rid28">28,52,53</a>]. While both cardiac (eg, arrhythmias, chest pain, left ventricular outflow tract obstruction, etc) and noncardiac side effects can occur, serious complications, such as ventricular fibrillation or myocardial infarction, are rare, occurring in approximately 1 of every 2000 studies [<a href="#rid3">3,52</a>]. <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">Atropine</a> poisoning was observed in 0.12 percent of patients [<a href="#rid52">52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Minor arrhythmias, predominantly ventricular and/or premature atrial complex (also referred to a premature atrial beat, premature supraventricular complex, or premature supraventricular beat), occur in up to 30 percent of <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress studies [<a href="#rid52">52,53</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation and nonsustained ventricular tachyarrhythmias occur in 1 and 3 percent of studies, respectively; these arrhythmias are generally well tolerated and spontaneously resolve [<a href="#rid52">52,53</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sustained ventricular tachycardia is rare, occurring in approximately 0.1 to 0.3 percent of studies, and the risk may be associated with left ventricular dysfunction and/or coronary artery disease [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although chest pain has been reported in up to 11 percent of patients receiving <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> for stress testing, serious complications from myocardial ischemia are very uncommon. In a review of more than 4000 patients, there was only one case of nonfatal myocardial infarction [<a href="#rid52">52</a>]. Symptomatic ischemia is effectively treated with discontinuation of dobutamine and sublingual <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> and/or intravenous beta-blocker.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">Dobutamine</a> can also induce left ventricular mid-cavity and outflow tract obstruction in 10 to 25 percent of patients [<a href="#rid55">55-57</a>]. </p><p></p><p>There are a number of minor noncardiac side effects including nausea, anxiety, headache, tremor, and urinary urgency, which can lead to test termination in approximately 3 percent of cases  (<a class="graphic graphic_table graphicRef77326" href="/z/d/graphic/77326.html" rel="external">table 2</a>) [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H197712028"><span class="h2">Ultrasound-enhancing agent safety</span><span class="headingEndMark"> — </span>Ultrasound-enhancing agents are generally safe to use for the evaluation of endocardial borders and wall motion [<a href="#rid58">58,59</a>]. The safety of these agents is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5301.html" rel="external">"Contrast echocardiography: Contrast agents, safety, and imaging technique", section on 'Second-generation contrast safety'</a>.)</p><p>As examples of the safety of ultrasound-enhancing agents during stress echocardiography:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective analysis of a multicenter cohort including more than 40,000 patients, rates of death and myocardial infarction were not significantly different between patients receiving ultrasound-enhancing agents and those not receiving these agents [<a href="#rid58">58</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pulmonary hypertension have been thought to have a higher risk of adverse reactions receiving ultrasound-enhancing agents, but an evaluation of more than 25,000 patients showed that right ventricular systolic pressure had no impact on adverse outcomes after receiving ultrasound-enhancing agents [<a href="#rid59">59</a>]. </p><p></p><p class="headingAnchor" id="H341670988"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119863.html" rel="external">"Society guideline links: Multimodality cardiovascular imaging appropriate use criteria"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122212.html" rel="external">"Society guideline links: Stress testing and cardiopulmonary exercise testing"</a>.)</p><p class="headingAnchor" id="H10049073"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– Similar to other modalities of stress testing (eg, exercise treadmill testing without imaging, radionuclide myocardial perfusion imaging, etc), the majority of stress echocardiograms are performed to evaluate for known or suspected coronary heart disease (CHD). Stress echocardiography is useful for the assessment of myocardial viability. In addition, because of its ability to assess hemodynamics, stress echocardiography can be useful in a variety of other non-CHD conditions (eg, valvular heart disease, hypertrophic cardiomyopathy, etc). (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stress techniques </strong>–<strong> </strong>Stress echocardiography can be accomplished using either exercise (treadmill or bicycle) or pharmacologic agents (predominantly <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>) as the mechanism of stress. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exercise stress is preferred to pharmacologic stress for patients who can perform an exercise test. Exercise echocardiography is most commonly performed using a treadmill protocol, with echocardiographic images acquired prior to and immediately after the peak treadmill exercise. However, supine and upright bicycle ergometry are other well validated methods of exercise echocardiography, with the major advantage of allowing for monitoring of wall motion and Doppler parameters during exercise. (See <a class="local">'Exercise two-dimensional echocardiography'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pharmacologic stress is employed in patients who are unable to perform exercise testing. In addition, it may be preferred to exercise testing for preoperative risk and myocardial viability assessment since the majority of data validating stress echocardiography for this indication involved pharmacologic (largely <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>) stress. During dobutamine echocardiography, echocardiographic images are acquired prior to the start of the dobutamine infusion, at the completion of each stage, at peak stress, and during recovery. (See <a class="local">'Pharmacologic stress echocardiography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on beta-blocker therapy </strong>– Use of beta blockers may attenuate heart rate response as well as evidence of myocardial ischemia during <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography. However, the effect of beta-blockers on heart rate response to dobutamine can usually be overcome by the administration of <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>. (See <a class="local">'Effect of beta blocker therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging techniques </strong>– The baseline (resting) echocardiogram obtained prior to stress testing should include a screening assessment of ventricular function, chamber sizes, left ventricular wall thicknesses, aortic root diameter, pericardial effusion, and gross valvular structure and function. The echocardiographic imaging protocol that is chosen for stress imaging should be tailored to the indication for the test. (See <a class="local">'Imaging techniques'</a> above.)</p><p></p><p><strong>Use of ultrasound-enhancing agents </strong>– Clinical characteristics suggesting the need for ultrasound-enhancing agents during stress echocardiography include older age, male sex, smoking, presence of multiple coronary artery disease risk factors, higher body mass index, chronic lung disease, referral for <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress, history of coronary artery disease, and abnormal baseline electrocardiogram. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety </strong>– There are no known adverse effects from diagnostic ultrasound at clinical imaging frequencies, so the addition of echocardiographic imaging to stress testing (either exercise or pharmacologic) does not alter the underlying risk of the stress test. As with any stress test, the patient's electrocardiogram, heart rate, and blood pressure should be monitored throughout the test and during recovery, and the patient should be frequently queried about the development of any symptoms. (See <a class="local">'Safety'</a> above and  <a class="medical medical_review" href="/z/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results"</a>.)</p><p></p><p class="headingAnchor" id="H2262956228"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Nelson Schiller, Dr. Xiushui Ren, and Dr. Bryan Ristow, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sicari R, Nihoyannopoulos P, Evangelista A, et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr 2008; 9:415.</a></li><li><a class="nounderline abstract_t">Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease: From the American Society of Echocardiography. J Am Soc Echocardiogr 2020; 33:1.</a></li><li><a class="nounderline abstract_t">Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007; 20:1021.</a></li><li><a class="nounderline abstract_t">American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. J Am Coll Cardiol 2011; 57:1126.</a></li><li><a class="nounderline abstract_t">Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 63:380.</a></li><li><a class="nounderline abstract_t">Best PJ, Tajik AJ, Gibbons RJ, Pellikka PA. The safety of treadmill exercise stress testing in patients with abdominal aortic aneurysms. Ann Intern Med 1998; 129:628.</a></li><li><a class="nounderline abstract_t">Pellikka PA, Roger VL, Oh JK, et al. Safety of performing dobutamine stress echocardiography in patients with abdominal aortic aneurysm &gt; or = 4 cm in diameter. Am J Cardiol 1996; 77:413.</a></li><li><a class="nounderline abstract_t">Applegate RJ, Dell'Italia LJ, Crawford MH. Usefulness of two-dimensional echocardiography during low-level exercise testing early after uncomplicated acute myocardial infarction. Am J Cardiol 1987; 60:10.</a></li><li><a class="nounderline abstract_t">Crouse LJ, Kramer PH. Exercise echocardiography: coming of age. J Am Coll Cardiol 1994; 24:115.</a></li><li><a class="nounderline abstract_t">Park TH, Tayan N, Takeda K, et al. Supine bicycle echocardiography improved diagnostic accuracy and physiologic assessment of coronary artery disease with the incorporation of intermediate stages of exercise. J Am Coll Cardiol 2007; 50:1857.</a></li><li><a class="nounderline abstract_t">Badruddin SM, Ahmad A, Mickelson J, et al. Supine bicycle versus post-treadmill exercise echocardiography in the detection of myocardial ischemia: a randomized single-blind crossover trial. J Am Coll Cardiol 1999; 33:1485.</a></li><li><a class="nounderline abstract_t">Kamaran M, Teague SM, Finkelhor RS, et al. Prognostic value of dobutamine stress echocardiography in patients referred because of suspected coronary artery disease. Am J Cardiol 1995; 76:887.</a></li><li><a class="nounderline abstract_t">Elhendy A, Trocino G, Salustri A, et al. Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction. Am Heart J 1996; 131:1088.</a></li><li><a class="nounderline abstract_t">Picano E, Mathias W Jr, Pingitore A, et al. Safety and tolerability of dobutamine-atropine stress echocardiography: a prospective, multicentre study. Echo Dobutamine International Cooperative Study Group. Lancet 1994; 344:1190.</a></li><li><a class="nounderline abstract_t">Piérard LA, Berthe C, Albert A, et al. Haemodynamic alterations during ischaemia induced by dobutamine stress testing. Eur Heart J 1989; 10:783.</a></li><li><a class="nounderline abstract_t">Picano E. Stress echocardiography. From pathophysiological toy to diagnostic tool. Circulation 1992; 85:1604.</a></li><li><a class="nounderline abstract_t">Picano E, Landi P, Bolognese L, et al. Prognostic value of dipyridamole echocardiography early after uncomplicated myocardial infarction: a large-scale, multicenter trial. The EPIC Study Group. Am J Med 1993; 95:608.</a></li><li><a class="nounderline abstract_t">Picano E, Ostojic M, Varga A, et al. Combined low dose dipyridamole-dobutamine stress echocardiography to identify myocardial viability. J Am Coll Cardiol 1996; 27:1422.</a></li><li><a class="nounderline abstract_t">McNeill AJ, Fioretti PM, el-Said SM, et al. Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. Am J Cardiol 1992; 70:41.</a></li><li><a class="nounderline abstract_t">Fioretti PM, Poldermans D, Salustri A, et al. Atropine increases the accuracy of dobutamine stress echocardiography in patients taking beta-blockers. Eur Heart J 1994; 15:355.</a></li><li><a class="nounderline abstract_t">Ling LH, Pellikka PA, Mahoney DW, et al. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. J Am Coll Cardiol 1996; 28:551.</a></li><li><a class="nounderline abstract_t">Burger AJ, Notarianni MP, Aronson D. Safety and efficacy of an accelerated dobutamine stress echocardiography protocol in the evaluation of coronary artery disease. Am J Cardiol 2000; 86:825.</a></li><li><a class="nounderline abstract_t">San Román JA, Sanz-Ruiz R, Ortega JR, et al. Safety and predictors of complications with a new accelerated dobutamine stress echocardiography protocol. J Am Soc Echocardiogr 2008; 21:53.</a></li><li><a class="nounderline abstract_t">Ling LH, Christian TF, Mulvagh SL, et al. Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 201 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography. Am Heart J 2006; 151:882.</a></li><li><a class="nounderline abstract_t">Garcia MJ, Kwong RY, Scherrer-Crosbie M, et al. State of the Art: Imaging for Myocardial Viability: A Scientific Statement From the American Heart Association. Circ Cardiovasc Imaging 2020; 13:e000053.</a></li><li><a class="nounderline abstract_t">Marwick T, Willemart B, D'Hondt AM, et al. Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mTc-MIBI single photon emission computed tomography. Circulation 1993; 87:345.</a></li><li><a class="nounderline abstract_t">Pellikka PA, Roger VL, Oh JK, et al. Stress echocardiography. Part II. Dobutamine stress echocardiography: techniques, implementation, clinical applications, and correlations. Mayo Clin Proc 1995; 70:16.</a></li><li><a class="nounderline abstract_t">Kane GC, Hepinstall MJ, Kidd GM, et al. Safety of stress echocardiography supervised by registered nurses: results of a 2-year audit of 15,404 patients. J Am Soc Echocardiogr 2008; 21:337.</a></li><li><a class="nounderline abstract_t">Chaowalit N, Maalouf JF, Rooke TW, et al. Prognostic significance of chronotropic response to dobutamine stress echocardiography in patients with peripheral arterial disease. Am J Cardiol 2004; 94:1523.</a></li><li><a class="nounderline abstract_t">Bergeron S, Hillis GS, Haugen EN, et al. Prognostic value of dobutamine stress echocardiography in patients with chronic kidney disease. Am Heart J 2007; 153:385.</a></li><li><a class="nounderline abstract_t">Chuah SC, Pellikka PA, Roger VL, et al. Role of dobutamine stress echocardiography in predicting outcome in 860 patients with known or suspected coronary artery disease. Circulation 1998; 97:1474.</a></li><li><a class="nounderline abstract_t">Strizik B, Chiu S, Ilercil A, et al. Usefulness of isometric handgrip during treadmill exercise stress echocardiography. Am J Cardiol 2002; 90:420.</a></li><li><a class="nounderline abstract_t">Khan IA, Otero FJ, Font-Cordoba J, et al. Adjunctive handgrip during dobutamine stress echocardiography: invasive assessment of myocardial oxygen consumption in humans. Clin Cardiol 2005; 28:349.</a></li><li><a class="nounderline abstract_t">Ryan T, Feigenbaum H. Exercise echocardiography. Am J Cardiol 1992; 69:82H.</a></li><li><a class="nounderline abstract_t">Ryan T, Segar DS, Sawada SG, et al. Detection of coronary artery disease with upright bicycle exercise echocardiography. J Am Soc Echocardiogr 1993; 6:186.</a></li><li><a class="nounderline abstract_t">Hecht HS, DeBord L, Sotomayor N, et al. Supine bicycle stress echocardiography: peak exercise imaging is superior to postexercise imaging. J Am Soc Echocardiogr 1993; 6:265.</a></li><li><a class="nounderline abstract_t">Hecht HS, DeBord L, Shaw R, et al. Digital supine bicycle stress echocardiography: a new technique for evaluating coronary artery disease. J Am Coll Cardiol 1993; 21:950.</a></li><li><a class="nounderline abstract_t">Hecht HS, DeBord L, Shaw R, et al. Supine bicycle stress echocardiography versus tomographic thallium-201 exercise imaging for the detection of coronary artery disease. J Am Soc Echocardiogr 1993; 6:177.</a></li><li><a class="nounderline abstract_t">Hecht HS, DeBord L, Shaw R, et al. Usefulness of supine bicycle stress echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1993; 71:293.</a></li><li><a class="nounderline abstract_t">Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.</a></li><li><a class="nounderline abstract_t">Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105:539.</a></li><li><a class="nounderline abstract_t">La Canna G, Alfieri O, Giubbini R, et al. Echocardiography during infusion of dobutamine for identification of reversibly dysfunction in patients with chronic coronary artery disease. J Am Coll Cardiol 1994; 23:617.</a></li><li><a class="nounderline abstract_t">Afridi I, Grayburn PA, Panza JA, et al. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J Am Coll Cardiol 1998; 32:921.</a></li><li><a class="nounderline abstract_t">Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol 1999; 33:1848.</a></li><li><a class="nounderline abstract_t">Dolan MS, Riad K, El-Shafei A, et al. Effect of intravenous contrast for left ventricular opacification and border definition on sensitivity and specificity of dobutamine stress echocardiography compared with coronary angiography in technically difficult patients. Am Heart J 2001; 142:908.</a></li><li><a class="nounderline abstract_t">Vlassak I, Rubin DN, Odabashian JA, et al. Contrast and harmonic imaging improves accuracy and efficiency of novice readers for dobutamine stress echocardiography. Echocardiography 2002; 19:483.</a></li><li><a class="nounderline abstract_t">Rainbird AJ, Mulvagh SL, Oh JK, et al. Contrast dobutamine stress echocardiography: clinical practice assessment in 300 consecutive patients. J Am Soc Echocardiogr 2001; 14:378.</a></li><li><a class="nounderline abstract_t">Thanigaraj S, Nease RF Jr, Schechtman KB, et al. Use of contrast for image enhancement during stress echocardiography is cost-effective and reduces additional diagnostic testing. Am J Cardiol 2001; 87:1430.</a></li><li><a class="nounderline abstract_t">Mulvagh SL, Rakowski H, Vannan MA, et al. American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am Soc Echocardiogr 2008; 21:1179.</a></li><li><a class="nounderline abstract_t">Bernier M, Abdelmoneim SS, Moir S, et al. Pretest score for predicting microbubble contrast agent use in stress echocardiography: a method to increase efficiency in the echo laboratory. Cardiol Res Pract 2009; 2009:308486.</a></li><li><a class="nounderline abstract_t">Varga A, Garcia MA, Picano E, International Stress Echo Complication Registry. Safety of stress echocardiography (from the International Stress Echo Complication Registry). Am J Cardiol 2006; 98:541.</a></li><li><a class="nounderline abstract_t">Mathias W Jr, Arruda A, Santos FC, et al. Safety of dobutamine-atropine stress echocardiography: A prospective experience of 4,033 consecutive studies. J Am Soc Echocardiogr 1999; 12:785.</a></li><li><a class="nounderline abstract_t">Sheldon SH, Askew JW 3rd, Klarich KW, et al. Occurrence of atrial fibrillation during dobutamine stress echocardiography: incidence, risk factors, and outcomes. J Am Soc Echocardiogr 2011; 24:86.</a></li><li><a class="nounderline abstract_t">Karabinos I, Kranidis A, Papadopoulos A, Katritsis D. Prevalence and potential mechanisms of sustained ventricular arrhythmias during dobutamine stress echocardiography: a literature review. J Am Soc Echocardiogr 2008; 21:1376.</a></li><li><a class="nounderline abstract_t">Pellikka PA, Oh JK, Bailey KR, et al. Dynamic intraventricular obstruction during dobutamine stress echocardiography. A new observation. Circulation 1992; 86:1429.</a></li><li><a class="nounderline abstract_t">Secknus MA, Niedermaier ON, Lauer MS, Marwick TH. Diagnostic and prognostic implications of left ventricular cavity obliteration response to dobutamine echocardiography. Am J Cardiol 1998; 81:1318.</a></li><li><a class="nounderline abstract_t">Dawn B, Paliwal VS, Raza ST, et al. Left ventricular outflow tract obstruction provoked during dobutamine stress echocardiography predicts future chest pain, syncope, and near syncope. Am Heart J 2005; 149:908.</a></li><li><a class="nounderline abstract_t">Dolan MS, Gala SS, Dodla S, et al. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience. J Am Coll Cardiol 2009; 53:32.</a></li><li><a class="nounderline abstract_t">Abdelmoneim SS, Bernier M, Scott CG, et al. Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study. Circ Cardiovasc Imaging 2010; 3:240.</a></li></ol></div><div id="topicVersionRevision">Topic 5310 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18579481" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31740370" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease: From the American Society of Echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765820" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349406" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24355759" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9786810" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The safety of treadmill exercise stress testing in patients with abdominal aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602573" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Safety of performing dobutamine stress echocardiography in patients with abdominal aortic aneurysm&gt;or = 4 cm in diameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3604923" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Usefulness of two-dimensional echocardiography during low-level exercise testing early after uncomplicated acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8006253" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Exercise echocardiography: coming of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980252" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Supine bicycle echocardiography improved diagnostic accuracy and physiologic assessment of coronary artery disease with the incorporation of intermediate stages of exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334412" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Supine bicycle versus post-treadmill exercise echocardiography in the detection of myocardial ischemia: a randomized single-blind crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7484826" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prognostic value of dobutamine stress echocardiography in patients referred because of suspected coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644586" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7934540" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Safety and tolerability of dobutamine-atropine stress echocardiography: a prospective, multicentre study. Echo Dobutamine International Cooperative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2806276" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Haemodynamic alterations during ischaemia induced by dobutamine stress testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1555297" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Stress echocardiography. From pathophysiological toy to diagnostic tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8259778" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prognostic value of dipyridamole echocardiography early after uncomplicated myocardial infarction: a large-scale, multicenter trial. The EPIC Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8626953" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Combined low dose dipyridamole-dobutamine stress echocardiography to identify myocardial viability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1615868" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8013509" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Atropine increases the accuracy of dobutamine stress echocardiography in patients taking beta-blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772738" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11024395" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Safety and efficacy of an accelerated dobutamine stress echocardiography protocol in the evaluation of coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17628422" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Safety and predictors of complications with a new accelerated dobutamine stress echocardiography protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16569554" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 201 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32833510" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : State of the Art: Imaging for Myocardial Viability: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425283" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mTc-MIBI single photon emission computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7808046" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Stress echocardiography. Part II. Dobutamine stress echocardiography: techniques, implementation, clinical applications, and correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17904811" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Safety of stress echocardiography supervised by registered nurses: results of a 2-year audit of 15,404 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589008" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prognostic significance of chronotropic response to dobutamine stress echocardiography in patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307417" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prognostic value of dobutamine stress echocardiography in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9576428" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Role of dobutamine stress echocardiography in predicting outcome in 860 patients with known or suspected coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161235" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Usefulness of isometric handgrip during treadmill exercise stress echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16075829" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adjunctive handgrip during dobutamine stress echocardiography: invasive assessment of myocardial oxygen consumption in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1605124" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Exercise echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8481247" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Detection of coronary artery disease with upright bicycle exercise echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8333974" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Supine bicycle stress echocardiography: peak exercise imaging is superior to postexercise imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450164" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Digital supine bicycle stress echocardiography: a new technique for evaluating coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8481246" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Supine bicycle stress echocardiography versus tomographic thallium-201 exercise imaging for the detection of coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8427170" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Usefulness of supine bicycle stress echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376782" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11815441" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113543" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Echocardiography during infusion of dobutamine for identification of reversibly dysfunction in patients with chronic coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768712" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362184" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11685180" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of intravenous contrast for left ventricular opacification and border definition on sensitivity and specificity of dobutamine stress echocardiography compared with coronary angiography in technically difficult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12356343" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Contrast and harmonic imaging improves accuracy and efficiency of novice readers for dobutamine stress echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11337683" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Contrast dobutamine stress echocardiography: clinical practice assessment in 300 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11397374" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Use of contrast for image enhancement during stress echocardiography is cost-effective and reduces additional diagnostic testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18992671" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19936116" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pretest score for predicting microbubble contrast agent use in stress echocardiography: a method to increase efficiency in the echo laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16893714" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety of stress echocardiography (from the International Stress Echo Complication Registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10511646" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Safety of dobutamine-atropine stress echocardiography: A prospective experience of 4,033 consecutive studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21172598" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Occurrence of atrial fibrillation during dobutamine stress echocardiography: incidence, risk factors, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19041580" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prevalence and potential mechanisms of sustained ventricular arrhythmias during dobutamine stress echocardiography: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1423956" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dynamic intraventricular obstruction during dobutamine stress echocardiography. A new observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631970" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Diagnostic and prognostic implications of left ventricular cavity obliteration response to dobutamine echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894976" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Left ventricular outflow tract obstruction provoked during dobutamine stress echocardiography predicts future chest pain, syncope, and near syncope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118722" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20233859" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
